Agios Pharmaceuticals (NASDAQ: AGIO) is a biopharmaceutical company that focuses on developing treatments for rare diseases, particularly in the field of rare hematology, which involves blood disorders. On June 15, 2026, analyst firm H.C. Wainwright showed confidence in the company by restating its Buy rating. It also raised its price target for Agios Pharmaceuticals to $54.00 from a previous level.
This positive outlook follows new clinical data from the company's drug pipeline. Agios Pharmaceuticals presented detailed results from its RISE UP Phase 3 trial for the drug mitapivat. The study shows that mitapivat creates a statistically significant improvement in hemoglobin response for patients with Sickle Cell Disease when compared to a placebo, which is a substance with no therapeutic effect.
Further analysis reveals that patients taking mitapivat experience a meaningful reduction in their need for blood transfusions. Those who respond well to the treatment also report significant benefits related to sickle cell pain crises and fatigue. Agios Pharmaceuticals confirms that mitapivat is well-tolerated, with a safety profile that matches results from earlier trials.
In a move to expand its drug portfolio, Agios Pharmaceuticals has entered an agreement to license the global rights for cevidoplenib from Oscotec, a South Korean biotech firm. This involves an upfront payment of $25.00 million from Agios Pharmaceuticals. The drug is a late-stage candidate for treating immune thrombocytopenia (ITP), another rare blood disorder.
As highlighted by Zacks, this deal gives Agios Pharmaceuticals a drug with the potential for up to $1.00 billion in peak U.S. sales. At the time of the analyst rating, shares of Agios Pharmaceuticals trade at $29.46, with a market capitalization of approximately $1.75 billion. Market capitalization is the total value of a company's shares.
